Original article
Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction
José Pedro L. Nunesa,b,, , Filipa Melãob, Ana Rita Godinhob, Joana D. Rodriguesb, Maria Júlia Maciela,b
a Faculdade de Medicina da Universidade do Porto, Porto, Portugal
b Department of Cardiology, Hospital São João, Porto, Portugal
Recebido 11 Janeiro 2017, Aceitaram 04 Fevereiro 2017
Abstract
Introduction

Diabetes mellitus is frequently associated to cardiovascular disease. We aimed at studying the relations between anti-diabetic drugs in use at admission by diabetic patients with acute myocardial infarction and survival after a period of at least 36 and up to 52 months after admission.

Methods

Retrospective study based on electronic records. Data from a total number of 195 admissions corresponding to different patients were under analysis.

Results

Kaplan–Meier analysis, as well as Cox analysis, failed to show a difference in survival associated to the use of DPP-4 inhibitors (n=35 patients). A non-significant trend toward increased survival was seen with metformin (n=92 patients), and in the opposite direction with both insulin (n=51 patients) and sulfonylureas (n=51 patients).

Conclusions

The use of DPP-4 inhibitors at admission, in patients with Diabetes mellitus admitted for acute myocardial infarction, was not associated to a different survival after no less than 36 months and up to 52 months after admission.

Highlights

  • Anti-diabetic drugs used at admission in myocardial infarction patients were studied.

  • 195 admissions corresponding to different patients were under analysis.

  • No difference in survival was seen in patients using or not using DPP-4 inhibitors.

Keywords
Acute myocardial infarction, Diabetes mellitus, DPP-4 inhibitors, Sulfonylureas

Open Access

Licença Creative Commons
Porto Biomedical Journal está licenciado com uma Licença Creative Commons - Atribuição-NãoComercial-SemDerivações 4.0 Internacional.

+ info